Trimethoprim, Sulfamethoxazole Drug Combination
"Trimethoprim, Sulfamethoxazole Drug Combination" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.
| Descriptor ID |
D015662
|
| MeSH Number(s) |
D02.065.884.725.867.500 D02.092.146.807.867.500 D02.886.590.700.725.867.500 D03.383.742.906.500 D26.310.875
|
| Concept/Terms |
Trimethoprim, Sulfamethoxazole Drug Combination- Trimethoprim, Sulfamethoxazole Drug Combination
- Centrin
- Cotrimoxazole
- Eslectin
- Insozalin
- TMP-SMX
- Trimethoprim-Sulfamethoxazole
- Trimethoprim Sulfamethoxazole
- Sulfamethoxazole-Trimethoprim Combination
- Sulfamethoxazole Trimethoprim Combination
- Trimethoprim-Sulfamethoxazole Combination
- Trimethoprim Sulfamethoxazole Combination
- Trimezole
- Co-Trimoxazole
- Co Trimoxazole
- TMP SMX
- Centran
- Trimedin
|
Below are MeSH descriptors whose meaning is more general than "Trimethoprim, Sulfamethoxazole Drug Combination".
Below are MeSH descriptors whose meaning is more specific than "Trimethoprim, Sulfamethoxazole Drug Combination".
This graph shows the total number of publications written about "Trimethoprim, Sulfamethoxazole Drug Combination" by people in this website by year, and whether "Trimethoprim, Sulfamethoxazole Drug Combination" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 2 | 0 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Trimethoprim, Sulfamethoxazole Drug Combination" by people in Profiles.
-
Pneumocystis jirovecii pneumonia in people living with HIV: a review. Clin Microbiol Rev. 2024 03 14; 37(1):e0010122.
-
Effect of Stopping Cotrimoxazole Preventive Therapy on Microbial Translocation and Inflammatory Markers Among Human Immunodeficiency Virus-Infected Ugandan Adults on Antiretroviral Therapy: The COSTOP Trial Immunology Substudy. J Infect Dis. 2020 07 06; 222(3):381-390.
-
Discontinuing cotrimoxazole preventive therapy in HIV-infected adults who are stable on antiretroviral treatment in Uganda (COSTOP): A randomised placebo controlled trial. PLoS One. 2018; 13(12):e0206907.
-
HIV-related pneumococcal disease prevention in adults. Expert Rev Respir Med. 2017 03; 11(3):181-199.
-
Longitudinal effect of CD4 by cotrimoxazole use on malaria incidence among HIV-infected Ugandan adults on antiretroviral therapy: a randomized controlled study. Malar J. 2016 07 15; 15:361.
-
Incidence of malaria by cotrimoxazole use in HIV-infected Ugandan adults on antiretroviral therapy: a randomised, placebo-controlled study. AIDS. 2016 Feb 20; 30(4):635-44.
-
Safety of discontinuing cotrimoxazole prophylaxis among HIV infected adults on anti-retroviral therapy in Uganda (COSTOP trial): Design. Contemp Clin Trials. 2015 Jul; 43:100-4.
-
Cotrimoxazole prophylaxis and tuberculosis risk among people living with HIV. PLoS One. 2014; 9(1):e83750.
-
HIV-infected ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/µL who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea. Clin Infect Dis. 2012 Apr; 54(8):1204-11.
-
Trimethoprim-sulfamethoxazole prophylaxis and antibiotic nonsusceptibility in invasive pneumococcal disease. Antimicrob Agents Chemother. 2012 Mar; 56(3):1602-5.